Reducing financial toxicity in bladder cancer care.

IF 2.1 3区 医学 Q2 UROLOGY & NEPHROLOGY Current Opinion in Urology Pub Date : 2024-11-01 Epub Date: 2024-08-30 DOI:10.1097/MOU.0000000000001218
Jeremy A Kurnot, Deborah R Kaye
{"title":"Reducing financial toxicity in bladder cancer care.","authors":"Jeremy A Kurnot, Deborah R Kaye","doi":"10.1097/MOU.0000000000001218","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Financial toxicity is a significant concern for many individuals with bladder cancer, which is, overall, the most expensive malignancy, per patient. Financial toxicity, defined as the harmful effects of treatment costs on an individual's quality of life, is associated with worse outcomes and decreased quality of life. Awareness of the objective and subjective factors that contribute to financial toxicity, and ways to mitigate their effects on patients, is essential to reduce the burden of bladder cancer care. This commentary aims to discuss the elements contributing to financial toxicity amongst bladder cancer patients, identify at-risk populations, and review current and potential strategies for mitigating financial burden.</p><p><strong>Recent findings: </strong>Bladder cancer is becoming more expensive as the use of novel therapies increases. Early data suggest how some of these novel treatments or changes in treatment delivery may impact costs. Potential innovative strategies for cost reduction include blue light cystoscopy, intravesical gemcitabine-docetaxel rather than BCG for high-risk nonmuscle-invasive patients, home BCG therapy, and surveillance guideline optimization. However, there is still much work to be done on the potential impacts of these treatment on financial toxicity. While there is a paucity of data on treatment changes to reduce financial toxicity, and cost data can be hard to access, clinicians can still reduce the financial burden of cancer care. Awareness, financial toxicity screening, cost communication, and/or early referral to financial navigators or other similar resources have the potential to reduce financial burden. Despite mounting evidence, these tools/techniques are largely underutilized.</p><p><strong>Summary: </strong>Many individuals with bladder cancer face significant financial toxicity, with the potential for this to worsen in the setting of rising treatment costs. Novel diagnostic and treatment modifications may reduce financial toxicity. However, awareness, screening, cost discussions, and utilization of financial navigators are tools/techniques that are currently available and should be used to reduce financial burden.</p>","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"484-488"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560494/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOU.0000000000001218","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: Financial toxicity is a significant concern for many individuals with bladder cancer, which is, overall, the most expensive malignancy, per patient. Financial toxicity, defined as the harmful effects of treatment costs on an individual's quality of life, is associated with worse outcomes and decreased quality of life. Awareness of the objective and subjective factors that contribute to financial toxicity, and ways to mitigate their effects on patients, is essential to reduce the burden of bladder cancer care. This commentary aims to discuss the elements contributing to financial toxicity amongst bladder cancer patients, identify at-risk populations, and review current and potential strategies for mitigating financial burden.

Recent findings: Bladder cancer is becoming more expensive as the use of novel therapies increases. Early data suggest how some of these novel treatments or changes in treatment delivery may impact costs. Potential innovative strategies for cost reduction include blue light cystoscopy, intravesical gemcitabine-docetaxel rather than BCG for high-risk nonmuscle-invasive patients, home BCG therapy, and surveillance guideline optimization. However, there is still much work to be done on the potential impacts of these treatment on financial toxicity. While there is a paucity of data on treatment changes to reduce financial toxicity, and cost data can be hard to access, clinicians can still reduce the financial burden of cancer care. Awareness, financial toxicity screening, cost communication, and/or early referral to financial navigators or other similar resources have the potential to reduce financial burden. Despite mounting evidence, these tools/techniques are largely underutilized.

Summary: Many individuals with bladder cancer face significant financial toxicity, with the potential for this to worsen in the setting of rising treatment costs. Novel diagnostic and treatment modifications may reduce financial toxicity. However, awareness, screening, cost discussions, and utilization of financial navigators are tools/techniques that are currently available and should be used to reduce financial burden.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
减少膀胱癌治疗中的经济毒性。
审查目的:经济毒性是许多膀胱癌患者非常关注的问题,总体而言,膀胱癌是每位患者花费最高的恶性肿瘤。经济毒性的定义是治疗费用对个人生活质量的有害影响,与较差的治疗效果和较低的生活质量有关。了解导致经济毒性的客观和主观因素,以及减轻这些因素对患者影响的方法,对于减轻膀胱癌治疗负担至关重要。本评论旨在讨论导致膀胱癌患者经济毒性的因素,确定高危人群,并回顾减轻经济负担的现有和潜在策略:随着新型疗法使用的增加,膀胱癌的治疗费用也越来越高。早期数据表明,其中一些新型疗法或治疗方法的改变可能会对费用产生影响。降低成本的潜在创新策略包括蓝光膀胱镜检查、膀胱内注射吉西他滨-多西他赛而非卡介苗治疗高风险非肌层浸润性患者、家庭卡介苗治疗以及监测指南优化。然而,这些治疗方法对经济毒性的潜在影响仍有许多工作要做。虽然有关改变治疗方法以减少经济毒性的数据很少,而且成本数据也很难获取,但临床医生仍可减轻癌症治疗的经济负担。提高认识、经济毒性筛查、费用沟通和/或及早转介给经济导航员或其他类似资源都有可能减轻经济负担。摘要:许多膀胱癌患者都面临着严重的经济负担,而在治疗费用不断上涨的情况下,经济负担有可能进一步加重。新的诊断和治疗方法可减少经济负担。不过,提高认识、筛查、费用讨论和利用财务导航员是目前可用的工具/技术,应加以利用以减轻经济负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Opinion in Urology
Current Opinion in Urology 医学-泌尿学与肾脏学
CiteScore
5.00
自引率
4.00%
发文量
140
审稿时长
6-12 weeks
期刊介绍: ​​​​​​​​Current Opinion in Urology delivers a broad-based perspective on the most recent and most exciting developments in urology from across the world. Published bimonthly and featuring ten key topics – including focuses on prostate cancer, bladder cancer and minimally invasive urology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.
期刊最新文献
Medical therapy for male infertility. A narrative review on the performance and outcomes of penile and scrotal surgery in the ambulatory setting. The role of MRI in muscle-invasive bladder cancer: an update from the last two years. Prostatectomy and other local treatments for oligometastatic prostate cancer: recent and ongoing trials. The changing landscape of nonobstructive azoospermia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1